Kaposi Sarcoma – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Kaposi Sarcoma – Pipeline Review, H2 2017’, provides an overview of the Kaposi Sarcoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Kaposi Sarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Kaposi Sarcoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Kaposi Sarcoma

The report reviews pipeline therapeutics for Kaposi Sarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Kaposi Sarcoma therapeutics and enlists all their major and minor projects

The report assesses Kaposi Sarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Kaposi Sarcoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Kaposi Sarcoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Kaposi Sarcoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aphios Corp

Bristol-Myers Squibb Co

Cannabis Science Inc

LATITUDE Pharmaceuticals Inc

Ono Pharmaceutical Co Ltd

RedHill Biopharma Ltd

Tumorend LLC

VasGene Therapeutics Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Kaposi Sarcoma - Overview 7

Kaposi Sarcoma - Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Pipeline by Universities/Institutes 10

Products under Development by Companies 11

Products under Development by Universities/Institutes 12

Kaposi Sarcoma - Therapeutics Assessment 13

Assessment by Target 13

Assessment by Mechanism of Action 15

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Kaposi Sarcoma - Companies Involved in Therapeutics Development 21

Aphios Corp 21

Bristol-Myers Squibb Co 21

Cannabis Science Inc 22

LATITUDE Pharmaceuticals Inc 22

Ono Pharmaceutical Co Ltd 22

RedHill Biopharma Ltd 23

Tumorend LLC 23

VasGene Therapeutics Inc 23

Kaposi Sarcoma - Drug Profiles 25

ABC-294640 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

aldoxorubicin hydrochloride - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

CM-101 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

CSTATI-1 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

Dermos - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

doxorubicin - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

ipilimumab + nivolumab - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

nivolumab - Drug Profile 65

R&D Progress 66

paclitaxel - Drug Profile 117

Product Description 117

Mechanism Of Action 117

R&D Progress 117

paclitaxel - Drug Profile 119

Product Description 119

Mechanism Of Action 119

R&D Progress 119

Synthetic Peptide to Inhibit HAUSP for Lymphoma and Kaposi Sarcoma - Drug Profile 120

Product Description 120

Mechanism Of Action 120

R&D Progress 120

TLD-208 - Drug Profile 121

Product Description 121

Mechanism Of Action 121

R&D Progress 121

Vas-01 - Drug Profile 122

Product Description 122

Mechanism Of Action 122

R&D Progress 122

Kaposi Sarcoma - Dormant Projects 124

Kaposi Sarcoma - Discontinued Products 126

Kaposi Sarcoma - Product Development Milestones 127

Featured News & Press Releases 127

Jun 06, 2016: CytRx Presents Updated Aldoxorubicin Clinical Trial Results at the 2016 American Society of Clinical Oncology Annual Meeting 127

May 26, 2016: $1.8 Million Fast-Track NIH SBIR Grant for Manocept Immunotherapeutics Evaluation in Kaposi’s Sarcoma Awarded to Navidea 128

May 03, 2016: Navidea and Macrophage Therapeutics to Provide Development Program Update 129

Apr 20, 2016: CytRx to Present Updated Aldoxorubicin Clinical Trial Data at the American Society of Clinical Oncology Annual Meeting in June 2016 129

Sep 03, 2015: Navidea Awarded $1.8M Fast Track NIH SBIR Grant for Evaluation of a Manocept Agent in Kaposi’s Sarcoma 130

Jul 02, 2015: Macrophage Therapeutics Reports Data Demonstrating a Manocept Drug Conjugate Induces Apoptosis in CD206 Positive Kaposi’s Sarcoma and Tumor Associated Macrophages 131

Jun 29, 2015: CytRx Announces Presentation of Interim Phase 2 Data for Aldoxorubicin for HIV-Related Kaposi's Sarcoma 132

Jan 20, 2015: CytRx Announces FDA's Removal of Partial Clinical Hold for Aldoxorubicin Clinical Trials Permitting Immediate Enrollment of New Patients 133

Jan 08, 2015: CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results as a Treatment for HIV-Related Kaposi's Sarcoma 133

Jan 23, 2014: CytRx Initiates Phase 2 Clinical Trial with Aldoxorubicin for First-Line Treatment of AIDS-Related Kaposi’s Sarcoma 134

Apr 26, 2013: Cannabis Science Announces Preclinical Development Program For CS-TATI-I 135

Nov 12, 2012: Beth Israel Deaconess Medical Center, Harvard Medical School Study Confirms Cannabis Science's Approach To Development Of CS-TATI-1 To Inhibit Kaposi Sarcoma 136

Sep 24, 2012: Cannabis Science Initiates Preclinical Investigation Of CS-TATI-1 For European Studies For Squamous/Basal Cell Carcinomas And Kaposi’s Sarcoma 137

Aug 13, 2012: CBIS Initiates GMP Development Plan For CS-TATI-1 137

Appendix 139

Methodology 139

Coverage 139

Secondary Research 139

Primary Research 139

Expert Panel Validation 139

Contact Us 139

Disclaimer 140

List of Tables

List of Tables

Number of Products under Development for Kaposi Sarcoma, H2 2017 8

Number of Products under Development by Companies, H2 2017 9

Number of Products under Development by Universities/Institutes, H2 2017 10

Products under Development by Companies, H2 2017 11

Products under Development by Universities/Institutes, H2 2017 12

Number of Products by Stage and Target, H2 2017 14

Number of Products by Stage and Mechanism of Action, H2 2017 16

Number of Products by Stage and Route of Administration, H2 2017 18

Number of Products by Stage and Molecule Type, H2 2017 20

Kaposi Sarcoma – Pipeline by Aphios Corp, H2 2017 21

Kaposi Sarcoma – Pipeline by Bristol-Myers Squibb Co, H2 2017 21

Kaposi Sarcoma – Pipeline by Cannabis Science Inc, H2 2017 22

Kaposi Sarcoma – Pipeline by LATITUDE Pharmaceuticals Inc, H2 2017 22

Kaposi Sarcoma – Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 23

Kaposi Sarcoma – Pipeline by RedHill Biopharma Ltd, H2 2017 23

Kaposi Sarcoma – Pipeline by Tumorend LLC, H2 2017 23

Kaposi Sarcoma – Pipeline by VasGene Therapeutics Inc, H2 2017 24

Kaposi Sarcoma – Dormant Projects, H2 2017 124

Kaposi Sarcoma – Dormant Projects, H2 2017 (Contd..1), H2 2017 125

Kaposi Sarcoma – Discontinued Products, H2 2017 126

List of Figures

List of Figures

Number of Products under Development for Kaposi Sarcoma, H2 2017 8

Number of Products under Development by Companies, H2 2017 9

Number of Products by Top 10 Targets, H2 2017 13

Number of Products by Stage and Top 10 Targets, H2 2017 13

Number of Products by Top 10 Mechanism of Actions, H2 2017 15

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 15

Number of Products by Routes of Administration, H2 2017 17

Number of Products by Stage and Routes of Administration, H2 2017 17

Number of Products by Molecule Types, H2 2017 19

Number of Products by Stage and Molecule Types, H2 2017 19

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports